Molecular Templates (MTEM) Competitors

Molecular Templates (NASDAQ:MTEM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Which has preferable earnings and valuation, MTEM or AMGN?

Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Templates	$23.48M	0.00	-$8.12M	-$2.70	N/A
Amgen	$33.42B	4.56	$4.09B	$7.55	37.59

Do analysts rate MTEM or AMGN?

Amgen has a consensus target price of $310.57, indicating a potential upside of 9.44%. Given Amgen's stronger consensus rating and higher possible upside, analysts plainly believe Amgen is more favorable than Molecular Templates.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Templates	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Amgen	2 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.43

Which has more risk & volatility, MTEM or AMGN?

Molecular Templates has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Does the MarketBeat Community prefer MTEM or AMGN?

Amgen received 1212 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.81% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.

Company	Underperform	Outperform
Molecular Templates	Outperform Votes 342 67.32%	Underperform Votes 166 32.68%
Amgen	Outperform Votes 1554 71.81%	Underperform Votes 610 28.19%

Do insiders & institutionals have more ownership in MTEM or AMGN?

95.5% of Molecular Templates shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 13.9% of Molecular Templates shares are owned by company insiders. Comparatively, 0.7% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is MTEM or AMGN more profitable?

Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Templates	-61.35%	-260.50%	-46.90%
Amgen	12.24%	176.32%	11.71%

Does the media prefer MTEM or AMGN?

In the previous week, Amgen had 51 more articles in the media than Molecular Templates. MarketBeat recorded 52 mentions for Amgen and 1 mentions for Molecular Templates. Amgen's average media sentiment score of 1.08 beat Molecular Templates' score of 0.64 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Templates	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	32 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amgen beats Molecular Templates on 15 of the 18 factors compared between the two stocks.